← Leaderboards
Ryan Turncliff
Alkermes, Inc.
$2,313,488
Attributed
$2,313,488
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2010–12$2M$1.5M$1M$500K$0
'10
'11
'12
Funding mix
By agency
NIH$2,313,488 · 1
By mechanism
R01$2,313,488 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Agonist”
- John M Lachin · George Washington University$118,921,924
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- Alan G. Barbour · University Of California Irvine$40,092,035
- Alexandros Makriyannis · University Of Connecticut Storrs$29,942,402
- Scott T Weiss · University Of California, San Diego$28,624,344
- John Didsbury · T3d Therapeutics, Inc.$25,150,614
Research focus
AgonistBehavioralBehavioral ModelBiological AvailabilityBody WeightBuprenorphineCharacteristicsClinical EfficacyClinical ResearchClinical TrialsCocaineCocaine AbuseCocaine DependencesCollaborationsCombination MedicationCuesDesignDoseDouble-Blind MethodDrug FormulationsDrug InteractionsDrug KineticsElectronicsAcute
Grant awards (3)
Clinical advancement of RDC-0313-buprenorphine: a novel approach to opioid recep$214,588
R01 · FY2012 · DA · contact PI
Clinical advancement of RDC-0313-buprenorphine: a novel approach to opioid recep$1,037,900
R01 · FY2011 · DA · contact PI
Clinical advancement of RDC-0313-buprenorphine: a novel approach to opioid recep$1,061,000
R01 · FY2010 · DA · contact PI